Experience of prophylaxis treatment in children with severe haemophilia

被引:65
|
作者
Yee, TT
Beeton, K
Griffioen, A
Harrington, C
Miners, A
Lee, CA
Brown, SA
机构
[1] UCL Royal Free & Univ Coll Med Sch, Haemophilia Ctr, Dept Primary Care & Populat Sci, London NW3 2QG, England
[2] UCL Royal Free NHS Trust, Haemophilia Ctr, London, England
[3] UCL Royal Free NHS Trust, Haemostasis Unit, London, England
[4] Univ Hertfordshire, Hatfield AL10 9AB, Herts, England
关键词
haemophilia; prophylaxis; joint scores; Port-a-Cath; inhibitor;
D O I
10.1046/j.1365-2516.2002.00630.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The practice of prophylactic treatment of boys with severe haemophilia has been evaluated in our centre. Prophylaxis was started at the median age of 3.7 years (range 0.4-12.7 years) in 38/41 children (93%) under 17 years of age. Median follow-up was 4.1 years (range 0.4-12.7 years). The criteria of primary prophylaxis according to the definition by the European Paediatric Network of Haemophilia Management was fulfilled by 9/38 (24%). Although a majority [76%, 29/38] of the children started prophylaxis after a median number of joint bleeds of 3.5, 70% of the children in this group had clinical joint scores of 0. Intravenous catheter insertion was required at a median age of 15.5 months (range 5-36 months) in 21% of the children, resulting in a catheter infection rate of 1.74 per 1000 catheter days. None developed an inhibitor on prophylaxis and three patients who had low-titre inhibitors (< 5 Bethesda units) prior to prophylaxis had undetectable inhibitors after prophylaxis. The home-treatment training programme required considerable time and cost. As a result, 87% of the children used peripheral venous access and hospital visits declined as prophylaxis became established. Parents' incentives for prophylaxis were that the children undertook many physical activities and sports previously not recommended, there was less parental anxiety and an overall improvement in the quality of life for the whole family.
引用
收藏
页码:76 / 82
页数:7
相关论文
共 50 条
  • [21] EMICIZUMAB TREATMENT IN CHILDREN WITH HAEMOPHILIA A: EXPERIENCE OF A SINGLE GREEK HAEMOPHILIA CENTRE
    Michalopoulou, A.
    Dettoraki, A.
    Kapsimali, Z.
    Margariti, K.
    Stamati, I.
    Politi, D.
    Mazarakis, M.
    Karelioti, H.
    Pergantou, H.
    HAEMOPHILIA, 2021, 27 : 71 - 71
  • [22] Bone mineral density in children with severe haemophilia receiving regular FVIII prophylaxis
    Heaney, N. B.
    Gibson, A.
    Khanna, S.
    Ahmed, F.
    Chalmers, E.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 1113 - 1113
  • [23] TREATMENT AND JOINT HEALTH STATUS IN CHILDREN WITH SEVERE HAEMOPHILIA ON PROPHYLAXIS: A COMPARISON OF SWEDEN AND GREECE BASED ON THE PEDNET REGISTRY
    Michalopoulou, A.
    Ranta, S.
    Andersson, N. Gretenkort
    Fischer, K.
    de Kovel, M.
    de Boer-Verdonk, E.
    Motwani, J.
    Pergantou, H.
    HAEMOPHILIA, 2023, 29 : 100 - 100
  • [24] Bone mineral density in children with severe haemophilia receiving regular FVIII prophylaxis
    Heaney, N. B.
    Gibson, A.
    Khanna, S.
    Ahmed, S. F.
    Chalmers, E. A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 : 73 - 73
  • [25] OUR EXPERIENCE IN SWEDEN WITH PROPHYLAXIS ON HAEMOPHILIA
    NILSSON, IM
    BLOMBACK, M
    AHALBERG, A
    BIBLIOTHECA HAEMATOLOGICA, 1970, (34): : 111 - &
  • [26] An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia
    Carcao, M. D.
    Avila, L.
    Leissinger, C.
    Blanchette, V. S.
    Aledort, L.
    HAEMOPHILIA, 2017, 23 (05) : e444 - e447
  • [27] Patient-determined discontinuation of regular prophylaxis for severe haemophilia: the west of Scotland experience
    Mccaig, A
    Chalmers, E
    Tait, RC
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 : 87 - 88
  • [28] Adherence to prophylaxis in adult patients with severe haemophilia A
    Bonanad, S.
    Garcia-Dasi, M.
    Aznar, J. A.
    Mingot Castellano, E.
    Jimenez Yuste, V.
    Calle, M.
    Palma, A.
    Fernandez Lopez, M.
    Marco, P.
    Paloma, M.
    Perez Garrido, R.
    Fernandez Mosteirin, N.
    Galmes, B.
    Sanabria, M.
    Alvarez, M.
    HAEMOPHILIA, 2019, 25 : 166 - 167
  • [29] Prophylaxis for severe haemophilia: clinical and economical issues
    Fischer, K
    Van den Berg, M
    HAEMOPHILIA, 2003, 9 (04) : 376 - 381
  • [30] Fitusiran prophylaxis in severe haemophilia without inhibitors
    Jimenez-Yuste, Victor
    Alvarez-Roman, Maria Teresa
    LANCET HAEMATOLOGY, 2023, 10 (05): : E308 - E309